CVS Health Corp stock holds steady as investors digest strong earnings and outlook
Published on 09/07/2026 at 22:26 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
CVS Health Corp stock (ISIN US1266501006) is in the spotlight after the healthcare group reported quarterly results with adjusted earnings per share of 2.58 dollars on revenue of 106.1 billion dollars, marking 7.3 percent year-over-year growth according to MarketBeat and updated guidance for 2026 in its Health Care Benefits segment reported on September 7, 2026 by Zacks.
Recent earnings beat and guidance for 2026
The most recent quarterly report for CVS Health covers the second quarter of 2026, with the company posting adjusted EPS of 2.58 dollars versus a consensus estimate of 1.87 dollars, a positive surprise of 0.71 dollars per share as highlighted by MarketBeat in its analysis of the filing dated September 7, 2026.
In the same Q2 2026 period, CVS Health generated revenue of 106.1 billion dollars, which represents an increase of 7.3 percent compared with the prior-year quarter’s 98.9 billion dollars, underscoring the continued expansion of its integrated pharmacy and health services platform as summarized by MarketBeat.
Aetna profitability focus and segment outlook
Beyond the headline quarterly numbers, CVS Health has sharpened its focus on improving the profitability of its Aetna health insurance business, with management raising the 2026 Health Care Benefits adjusted operating income outlook to a range of 5.03 billion to 5.37 billion dollars, according to a report on September 7, 2026 from Zacks.
This updated 2026 operating income guidance for Health Care Benefits sits above earlier expectations and serves as a key reference point for investors evaluating the long-term earnings power of CVS Health, especially when compared with the company’s current fiscal 2026 guidance for overall EPS of 7.90 to 8.10 dollars, as cited by MarketBeat in its review of analyst forecasts.
Dividend policy and earnings trajectory
CVS Health has also maintained a quarterly dividend of 0.665 dollars per share, which translates into an annualized dividend of 2.66 dollars and an indicated yield of 2.7 percent based on recent share prices, as documented by MarketBeat.
For fiscal year 2026, equities research analysts collectively forecast that CVS Health will deliver EPS of around 8.02 dollars, positioning the company’s earnings trajectory slightly above the midpoint of management’s 7.90 to 8.10 dollar guidance range for the same period, again according to aggregated estimates reported by MarketBeat.
Valuation and analyst stance on CVS Health stock
From a valuation perspective, CVS Health shares are trading at a forward five-year price-to-sales ratio of 0.29, materially below an industry average of about 0.50, which gives the stock a Value Score of A in the framework used by Zacks as of September 7, 2026.
Despite this apparent discount, CVS Health currently carries a Zacks Rank of 3, corresponding to a Hold rating, indicating that while the earnings outlook is improving and the valuation is relatively attractive, analysts see a balanced risk-reward profile in the near term, as described by Zacks.
Ownership changes and institutional interest
Institutional investors have been active in CVS Health, with asset manager Amundi increasing its stake in the company by 2.1 percent in the second quarter of 2026, bringing its holdings to approximately 7.53 million shares valued at about 778.5 million dollars, according to a filing-based summary from MarketBeat dated September 7, 2026.
This incremental purchase of roughly 154,000 additional CVS shares by Amundi in Q2 2026 illustrates continued institutional confidence in the company’s integrated healthcare model and its potential to translate operational improvements at Aetna and other segments into sustained earnings growth, even as the broader health care sector remains competitive.
CVS Pharmacy brand and retail presence
Alongside its insurance and pharmacy benefit management operations, CVS Health’s most visible product for consumers is the CVS Pharmacy retail chain, which operates thousands of locations across the United States, providing prescription dispensing, over-the-counter products and basic health services such as vaccinations and minute clinics.
The CVS Pharmacy network is a key contributor to the company’s overall revenue base and serves as a physical point of integration with its digital offerings and insurance plans, reinforcing the company’s strategy of delivering healthcare solutions across retail, home and virtual channels while supporting the earnings and guidance figures investors are currently watching for 2026.
Stock context and investor perspective
With U.S. stock markets closed on September 7, 2026 in observance of Labor Day as noted by CBS News, the latest completed trading session for CVS Health stock is the prior business day, meaning that the current reference price and market capitalization figures for the company are as of September 4, 2026 based on standard exchange data.
On that last trading day before the holiday, CVS Health shares traded on their primary listing at the New York Stock Exchange in United States dollars, and the price levels used by analysts to derive the 2.7 percent dividend yield and the forward price-to-sales ratio of 0.29 reflect this NYSE quotation as summarized in the valuation and dividend metrics reported by Zacks and MarketBeat.
Key data on CVS Health Corp stock
- Company: CVS Health Corp
- ISIN: US1266501006
- Ticker: CVS
- Trading venue: NYSE
- Sector / Industry: Health Care / Health Care Services
- Index membership: S&P 500
